Q-VANT Biosciences

Next-generation sustainable quillaja-saponins for pharamaceuticals.

[Q-VANT Biosciences @qvantbio]

Our scientific team in our labs in Chile are saponins experts, focused on obtaining new fractions of Quillaja saponaria. The ultimate goal: the next generation QS-21 adjuvant to enhance efficacy, cost, and sustainability in vaccine production. Learn more: https://t.co/qkfiT8zITu

[Q-VANT Biosciences @qvantbio]

#ICYMI Q-VANT signed a Master Agreement with @KSUCVM to test & evaluate its saponin-based adjuvants in several of the university’s veterinary vaccines.

Learn more about the Master Agreement on our website: https://t.co/caiURBZLFW

[Q-VANT Biosciences @qvantbio]

Meet the @qvantbio team: Elias Atala Riffo, Technology & Project Manager

Elias has 10 years of experience in chemistry R&D, purification & the application of quillaja saponins. He contributes to the industrial-scale production of #pharmaceutical-grade quillaja-based #adjuvants.

[Q-VANT Biosciences @qvantbio]

Meet the @qvantbio team: Bruce Forrest

Bruce is the Chief Scientific Officer at Q-VANT Biosciences, leading our R&D efforts. He has more than 25 years of global leadership experience in the development and commercialization of vaccines and adjuvants.

[Q-VANT Biosciences @qvantbio]

Meet the @qvantbio team: Stein Løkstad

Stein is the VP of Business Development at Q-VANT Biosciences and assists in solving the #pharmaceutical industry’s #sustainability challenge of limited #Quillaja saponin-based adjuvants used in life-saving #vaccines.

[Q-VANT Biosciences @qvantbio]

Meet the @qvantbio team: Jack Love, VP of Regulatory Affairs

Jack has 25+ years of #pharmaceutical experience and was the AVP of Regulatory Affairs for #Pfizer Vaccines. In his role at Q-VANT, Jack provides strategic guidance on #QS21 and related #saponin products.

[Q-VANT Biosciences @qvantbio]

This #WorldMalariaDay, the @qvantbio team stands with those that champion for the continued investment into malaria prevention & control. Learn more about the disease that threatens nearly half of the world’s population: https://t.co/pfjzWI9NF1

[Q-VANT Biosciences @qvantbio]

#ICYMI @qvantbio signed a vaccine research Master Agreement w/ Kansas State University’s College of Veterinary Medicine @KSUCVM to test & evaluate its #saponin-based #adjuvants in some of the university’s veterinary #vaccines. Read more @DrugDiscoverDev: https://t.co/KeDhs2sjud

[Q-VANT Biosciences @qvantbio]

Today, @qvantbio signed a vaccine research Master Agreement with Kansas State University’s College of Veterinary Medicine (@KSUCVM) to test and evaluate its #saponin-based #adjuvants in several of the university’s veterinary #vaccines. Learn more: https://t.co/5KJhBtSl3O

[Q-VANT Biosciences @qvantbio]

More than 13 million deaths around the world each year are due to avoidable environmental causes, according to @WHO. This #WorldHealthDay, learn more about the urgent actions needed to keep humans & the planet healthy: https://t.co/o2vlFEqQGu

[Q-VANT Biosciences @qvantbio]

Today is the beginning of National Public Health Week and this year’s theme is “Public Health is Where You Are.” It’s important that we all consider steps to take to build healthier, stronger, and safer communities. Learn more: https://t.co/UDBBNQ7FKX

[Q-VANT Biosciences @qvantbio]

#DYK that healthcare is responsible for more global CO2 emissions than the aviation or shipping industries? Our team understands the link between human health & environmental health as we work towards taking the carbon out of #vaccineadjuvant production: https://t.co/C0UVMNCdVT

[Q-VANT Biosciences @qvantbio]

The CEO of @qvantbio Doug Klaiber spoke with Drug Discovery & Development to discuss how we’re rewriting the narrative for #Quillaja saponin-based #adjuvants. Read about our technology that can increase the production volume of QS-21: https://t.co/QT2DvIbZ2S

[Q-VANT Biosciences @qvantbio]

According to the @CDC, one million people get shingles every year. This #ShinglesAwarenessMonth, the @qvantbio team reinforces our commitment to providing sustainable QS-21, a vital component of the FDA approved @GSK Shingrix shingles vaccine. https://t.co/gQRZtWYXuB

[Q-VANT Biosciences @qvantbio]

#ICYMI: @qvantbio signed an agreement with Sweden-based In vitro Plant-tech, whose technology will help us produce #Quillajasaponaria biomass anywhere in the world. Learn more in our press release: https://t.co/jv41KW7XXN

[Q-VANT Biosciences @qvantbio]

.@qvantbio announced today our agreement with In vitro Plant-tech, whose technology will help us produce #Quillajasaponaria biomass anywhere in the world. Our team is excited to continue to provide #sustainable #adjuvants for pharmaceuticals. Learn more: https://t.co/jv41KW7XXN

[Q-VANT Biosciences @qvantbio]

Check out the latest @DCVelocity article which explains how our technology has the potential to #sustainably meet the growing demand for the tree-derived #QS-21 compound used in pharmaceuticals & food additives. Read about our plans to ramp up production: https://t.co/q84GPkjGHL

[Q-VANT Biosciences @qvantbio]

Quillaja-based adjuvants play a big role in vaccine development. 17+ developmental vaccines use QS-21 in their formula, so the pressure to boost QS-21 production is more intense than ever. Read about Q-VANT’s solution to the potential #supplychain problem: https://t.co/F17Mlr94Rn

[Q-VANT Biosciences @qvantbio]

The demand for saponins extracted from quillaja tree bark is high, & the current harvesting process could damage forests & limit the availability of QS-21. Read about Q-VANT's sustainable way to produce QS-21 that also increases production volume by 1,000%:https://t.co/cDy6qQUeCy

[Q-VANT Biosciences @qvantbio]

Sustainable supply is critical in ensuring the delivery of #vaccines, according to Bruce Forrest, our Chief Scientific Officer. Bruce explains how Q-VANT’s #technology has the potential to ensure #QS-21 supply is met in our latest blog: https://t.co/Cs8lQ7B3wN